ArticleFrontiers in neurology2025
Predictive value of the combined DTI-ALPS index and serum creatinine levels in mild cognitive impairment in Parkinson's disease.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The glymphatic system and Parkinson's disease: a narrative review.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Review
- Preventing Parkinson's disease in the context of movement disorders: a narrative review of current evidence and future directions.Neurological research and practice · 2026Review
- A Machine Learning and Traditional Chinese Medicine Constitution-Based Prediction Model for Mild Cognitive Impairment in Community-Dwelling Older Adults.Neuropsychiatric disease and treatment · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To identify independent risk factors for Parkinson disease mild cognitive impairment (PD-MCI) and develop a prediction model integrating clinical indicators, blood biomarker, and neuroimaging data, aiding in detection and intervention. Methods: A retrospective study was conducted with 150 PD patients. The PD-MCI group ( Results: Significant differences between the groups were found in levodopa equivalent daily dose (LEDD), PD Quality of Life Questionnaire, creatinine, cystatin C, and ALPS index. Multivariate regression identified higher LEDD (OR = 1.01, 95%CI 1.00-1.03, Conclusion: This study developed a PD-MCI prediction model incorporating DTI-ALPS and clinical blood biomarkers. It confirmed that LEDD and creatinine levels are independent risk factors, with high clinical value for early screening and individualized treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.